ZA201007914B - Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis - Google Patents

Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Info

Publication number
ZA201007914B
ZA201007914B ZA2010/07914A ZA201007914A ZA201007914B ZA 201007914 B ZA201007914 B ZA 201007914B ZA 2010/07914 A ZA2010/07914 A ZA 2010/07914A ZA 201007914 A ZA201007914 A ZA 201007914A ZA 201007914 B ZA201007914 B ZA 201007914B
Authority
ZA
South Africa
Prior art keywords
arthritis
subjects
development
preventing
undifferentiated
Prior art date
Application number
ZA2010/07914A
Other languages
English (en)
Inventor
Michael Corbo
Jean-Claude Becker
George Vratsanos
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201007914(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201007914B publication Critical patent/ZA201007914B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
ZA2010/07914A 2008-05-05 2010-11-04 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis ZA201007914B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
ZA201007914B true ZA201007914B (en) 2011-07-27

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07914A ZA201007914B (en) 2008-05-05 2010-11-04 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Country Status (25)

Country Link
US (3) US7915222B2 (https=)
EP (2) EP2279206B1 (https=)
JP (1) JP2011522795A (https=)
KR (1) KR20110014180A (https=)
CN (1) CN102037010A (https=)
AR (1) AR071672A1 (https=)
AU (1) AU2009244448B2 (https=)
BR (1) BRPI0912249A2 (https=)
CA (1) CA2723698C (https=)
CL (1) CL2009001082A1 (https=)
DK (1) DK2279206T3 (https=)
EA (1) EA201001749A1 (https=)
ES (1) ES2539840T3 (https=)
HK (1) HK1208230A1 (https=)
HR (1) HRP20150552T1 (https=)
HU (1) HUE025256T2 (https=)
IL (1) IL208691A (https=)
MX (1) MX2010011503A (https=)
NZ (1) NZ589020A (https=)
PL (1) PL2279206T3 (https=)
PT (1) PT2279206E (https=)
SI (1) SI2279206T1 (https=)
TW (2) TW201444575A (https=)
WO (1) WO2009137424A1 (https=)
ZA (1) ZA201007914B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP2766394B1 (en) * 2011-10-10 2017-11-22 Medimmune Limited Treatment for rheumatoid arthritis
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
EP2914292A4 (en) * 2012-10-30 2016-05-04 Univ Emory Stimulation of bone formation by inhibition of CD28-co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
KR20160145789A (ko) * 2014-04-25 2016-12-20 브리스톨-마이어스 스큅 컴퍼니 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2154487A1 (en) * 1993-01-21 1994-08-04 Nicholas S. Hill Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
IL125928A (en) 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2001095928A2 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1372696T1 (sl) 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
AU2002243905B2 (en) 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
DE60335024D1 (de) 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2762015A1 (en) 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
CA2619429A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
EP2253644B1 (en) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
PL2279206T3 (pl) 2015-09-30
HUE025256T2 (en) 2016-02-29
DK2279206T3 (en) 2015-07-27
NZ589020A (en) 2012-05-25
US20130195865A1 (en) 2013-08-01
HK1148291A1 (en) 2011-09-02
EP2279206A4 (en) 2011-05-25
SI2279206T1 (sl) 2015-08-31
CA2723698C (en) 2018-03-06
HRP20150552T1 (hr) 2015-06-19
AU2009244448A1 (en) 2009-11-12
IL208691A0 (en) 2010-12-30
TWI454278B (zh) 2014-10-01
EP2279206B1 (en) 2015-04-22
CL2009001082A1 (es) 2010-02-12
TW200948381A (en) 2009-12-01
WO2009137424A1 (en) 2009-11-12
CN102037010A (zh) 2011-04-27
EA201001749A1 (ru) 2011-06-30
US9012408B2 (en) 2015-04-21
EP2279206A1 (en) 2011-02-02
US8435952B2 (en) 2013-05-07
US20090280119A1 (en) 2009-11-12
US20110142835A1 (en) 2011-06-16
JP2011522795A (ja) 2011-08-04
TW201444575A (zh) 2014-12-01
AR071672A1 (es) 2010-07-07
MX2010011503A (es) 2010-11-09
EP2891665A1 (en) 2015-07-08
IL208691A (en) 2015-01-29
BRPI0912249A2 (pt) 2015-10-20
PT2279206E (pt) 2015-07-27
AU2009244448B2 (en) 2014-07-31
CA2723698A1 (en) 2009-11-12
ES2539840T3 (es) 2015-07-06
US7915222B2 (en) 2011-03-29
KR20110014180A (ko) 2011-02-10
HK1208230A1 (en) 2016-02-26

Similar Documents

Publication Publication Date Title
IL208691A0 (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
IL244197A0 (en) Antibodies against cd100 and methods of using them
EP2508487A4 (en) WASTEWATER PRETREATMENT METHOD AND EFFLUENT TREATMENT METHOD USING THE PRETREATMENT PROCESS
IL250624A0 (en) Anti-fgfr3 antibodies and methods of using them
EP2262038A4 (en) Cell selector and cell with it
HUE067627T2 (hu) Szeparátor és az azt tartalmazó lítium szekunder akkumulátor
EP2164981A4 (en) METHODS AND DEVICES FOR DETERMINING ANALYTES
PL3281952T3 (pl) Antygen związany z reumatoidalnym zapaleniem stawów
PL2394156T3 (pl) Układ i sposób do pomiaru elektrochemicznego reakcji biochemicznych jak też sposób wytworzenia takiego układu
EP2343759A4 (en) BATTERY COMPONENT AND BATTERY
AP2011005536A0 (en) Treatment of rheumatoid arthritis with mammal betadefensins.
GB0903151D0 (en) Antibody uses and methods
IL219136A0 (en) Anti-hepsin antibodies and methods using same
FI20095020L (fi) Menetelmä aukirullaimen yhteydessä
IL216389A0 (en) Solar field and method for assembling the solar field
TWI372256B (en) Test apparature and test method
GB0822140D0 (en) Methods and reagents
PL2103942T3 (pl) Sposób określania charakteru zapalnej choroby reumatycznej w płynie maziowym
GB0707069D0 (en) Methods and uses
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses
GB0819611D0 (en) Electrochemical cells and components thereof
PL385706A1 (pl) System komputerowy i sposób korzystania z komputera
GB0920256D0 (en) Elecrochemical cells and components thereof